India mulls easing fuel efficiency norms for small cars sought by Suzuki, sources say
NEW DELHI, June 26 (Reuters) - India is considering relaxing fuel efficiency norms for small cars after lobbying by Maruti Suzuki (MRTI.NS), opens new tab, which has seen sales of such cars drop amid an SUV boom, industry and government sources told Reuters.
Small cars have been key to Maruti's success in India and account for most of its sales there. However, declining demand for small models, such as Alto or Wagon-R, has driven their share in the carmaker's sales to less than 50% of the 1.7 million cars it sold last fiscal year from nearly two-thirds two years ago.
India is also concerned about falling sales of small, affordable cars, according to a senior government official, and the country's top carmaker recently made the case for more favourable fuel emission norms arguing slumping sales will hurt overall growth of the passenger vehicle market.
"There should be more benefit for small cars. Maruti has been asking for that and we agree," the official said, explaining the rationale behind the planned move.
Under its Corporate Average Fuel Efficiency norms, India currently links the quantity of permissible carbon dioxide emissions to the vehicle's weight for all cars weighing less than 3,500 kg (7,716 lb).
The planned easing would relax such limits for cars weighing less than 1,000 kg, three people said, without sharing specific details of the reduction.
To meet the norms and avoid penalties, carmakers need to sell a certain percentage of low-emission models, mainly electric vehicles.
Relaxing the limits for small cars, means less pressure to electrify them, which will benefit those with the larger share of such models in their lineup, they said.
With 10 of its current 17 models weighing less than 1,000 kg, Maruti stands to gain the most.
Other carmakers with at least one small model on sale include Hyundai Motor (005380.KS), opens new tab, (HYUN.NS), opens new tab, JSW MG Motor, Renault (RENA.PA), opens new tab and Toyota Motor (7203.T), opens new tab.
India's ministry of heavy industries did not respond to a request seeking comment.
Maruti did not respond to an email seeking comment, but its Japanese parent Suzuki Motor (7269.T), opens new tab said in a 2024 sustainability report that small cars were good for the environment not just because of their lower emissions but also because fewer materials and less energy were needed to make them.
In a closed-door meeting on June 17, the ministry asked carmakers, including Tata Motors, Mahindra & Mahindra and Volkswagen, if they agreed to give small cars more leeway in the next set of fuel efficiency norms that will apply from April 2027, three people said.
The companies are yet to respond, but any preferential treatment will be a departure from a previously agreed consensus and could be seen as giving Maruti an unfair advantage, four sources said.
Tata (TAMO.NS), opens new tab, Mahindra (MAHM.NS), opens new tab, Volkswagen (VOWG.DE), opens new tab, Hyundai, JSW MG Motor and Toyota also did not respond to emails seeking comment.
Renault's country head, Venkatram Mamillapalle, said the company is confident that India's auto trade body will "represent the collective voice of the industry ... that benefits all stakeholders".
Four people familiar with the matter said that applying different norms based on a car's weight or size has not come up during months of consultations between the government and automakers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
an hour ago
- Telegraph
GSK to slash cost of malaria jab by more than half
The manufacturers of the world's first malaria vaccine are set to slash the price by more than half by 2028 to less than £4 per dose. On Wednesday the manufacturers of the shot, known as RTS,S, said a phased reduction in cost would begin immediately, with an ultimate aim to reduce the price to less than $5 (£3.64). The announcement could hardly come at a more critical moment. Gavi, a major vaccination initiative which funds immunisations in the world's poorest countries, is facing a major budget crunch. In Brussels on Wednesday, Gavi's replenishment event raised $9 billion (£6.55bn) to fund immunisation programmes over the next five years. While this sounds like a huge sum, it's significantly less than the $11.9bn the group had been aiming for. Governments around the world are cutting development spending dramatically. The UK, for instance, cut its contribution to Gavi by 40 per cent in real terms, telling The Telegraph it was prioritising defence, while the US has pledged nothing at all. Though America previously gave Gavi roughly $300m a year, the country's new health secretary claimed without evidence that the organisation was ignoring vaccine safety. The announcement from the British pharmaceutical giant GSK and Indian drugmaker Bharat Biotech will therefore be a relief to those trying to balance the books. Closing the gap between supply and need In a statement the companies said the price reduction demonstrated their 'commitment to Gavi', and was 'driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins'. By the time the price has fallen to below $5 per dose, a technology transfer agreement means Bharat will have taken over production, though GSK will continue to supply the adjuvant piece of the shot. 'For us, this is more than a cooperation, it's a promise,' said Dr Krishna Ella, Executive Chairman of Bharat Biotech International Limited. 'By joining forces with GSK, and working closely with Gavi, and the WHO [World Health Organization], we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria.' Each year, malaria still kills 500,000 people – the vast majority of them children aged five and under in sub-Saharan Africa. According to WHO estimates, cases and deaths fell significantly between 2000 and 2015, but progress has since stalled. Some have high hopes that RTS,S, as well as another vaccine called R21 developed by Oxford University, could prove critical in efforts to turn the tide. In clinical trials, RTS,S reduced hospitalisations for severe malaria by 30 per cent. But critics say the shot is too expensive and not as effective as existing tools, such as bed nets and antimalarials. The reduction in price will bring it more in line with the cost of R21, which is priced at around $4 per dose (roughly £3). Yet the cost will still add up, as both jabs require multiple shots. For RTS,S, this means four doses – the first three doses are given monthly, starting around five months of age, while the fourth dose is administered 15-18 months later. Both jabs 'provide reasonable short term efficacy – over about a year – so are a useful addition to other measures,' said Professor Nick White, a professor at the Mahidol-Oxford Tropical Medicine Research Unit who specialises in malaria. 'In the past GSK had limited production capacity – one of the reasons the R21 was developed. So reducing the price will be good and the two comparable vaccines can fight it out in the market place.' A spokesperson for Gavi said the alliance's goal is to 'create sustainable demand backed by predictable financing so that companies – like GSK and Bharat – can continue investing in technology transfer and other efficiencies that bring down costs, thus making critical vaccines more available and affordable. GSK's decision to lower its prices, the spokesperson added, is 'an important step for the global malaria vaccination programme, and our ability to make this lifesaving tool more widely available to those who need it the most'. Gavi plans to help fund RTS,S in 12 African countries by the end of this year. Previously, GSK has said it will supply up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028, a spokesperson told Reuters.
Reuters
2 hours ago
- Reuters
Bond giant PIMCO sees emerging markets in 'Goldilocks' moment
June 26 (Reuters) - Emerging markets are enjoying a "Goldilocks" moment, heavyweight bond fund PIMCO told Reuters, as U.S. President Donald Trump's erratic policy moves push the dollar down and send investors away from U.S. assets. "This is the most prominent capital rotation we have seen for the best part of two decades ... and we still think we are in the early innings of this," said Pramol Dhawan, PIMCO's head of EM portfolio management, outlining the $2 trillion asset manager's second-half view on emerging markets, where the firm holds some $70 billion in assets. "We are very constructive on the asset class, we think it is a Goldilocks-type backdrop for EM assets," he said, pointing partly to investor overexposure to the U.S. and a weakened dollar. PIMCO is the latest asset manager to warm to emerging market assets with EM local currency debt enjoying record inflows in recent weeks. The rotation is driven by import tariffs, rising concerns over U.S. debt levels and some loss of confidence in the government there, Dhawan said. Parts of Europe, Asia, and Latin America are the preferred destinations. The dollar index (.DXY), opens new tab is down 10% year-to-date while emerging currencies (.MIEM00000CUS), opens new tab have gained nearly 7%. "Flows have been very strong for the first time in a number of years," Dhawan said. Flows to local currency assets outstripping money headed for emerging market hard currency ones was "a sign of investors' willingness to embrace the dollar depreciation story and think more internationally around a search for yield." Emerging stocks (.MSCIEF), opens new tab are outperforming the S&P 500 (.SPX), opens new tab so far this year by 10 percentage points, while local currency bonds have returned more than 11% this year in dollar terms. (.JPMGBIEM), opens new tab U.S.-based investors did not have sufficient exposure to and were trying to figure out if this rally has durability, Dhawan said. "EM is in a good position where the underlying fundamentals are pretty healthy and robust," he said, adding that he did not expect capital flows to stop. Net capital inflows from non-residents to emerging markets are estimated at $887 billion in 2025, up from $852 billion in 2024, and forecast to hit $935 billion next year, according to the Institute of International Finance. Investor interest was also more broad based, Dhawan said, adding that the institutional investor base had become more established in emerging markets. Dhawan dismissed the risk of a policy reversal under Trump that could trigger a spike in the dollar. "These capital flows are genies that can't be put back in the bottle because they are irrespective of what the U.S. does now, there's been some loss of confidence in the administration."
Reuters
2 hours ago
- Reuters
India's Credila Financial Services files for $584 million IPO
June 26 (Reuters) - Credila Financial Services on Thursday filed for an initial public offering worth 50 billion rupees ($583.76 million), draft prospectus showed. ($1 = 85.6520 Indian rupees)
